Dark

Check out our API

BCTXF
Briacell Therapeutics Corp. Common Shares
stock OTC

Inactive

Feb 23, 2021

5.95USD-1.315%(-0.08)2,095

Pre-market

0.00USD-100.000%(-6.03)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Apr 12, 2021

06:32AM EDT BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021 Benzinga

Mar 30, 2021

06:30AM EDT BriaCell Therapeutics to Present at the American Association for GlobeNewswire Inc

Feb 26, 2021

02:25PM EST BriaCell Announces Closing of US$25 Million Public Offering GlobeNewswire Inc

Feb 23, 2021

11:06PM EST BriaCell Announces Pricing of US$25 Million Public Offering and GlobeNewswire Inc

Jan 26, 2021

06:30AM EST Clinical and pathological findings presented from the clinical trials of Bria-IMT alone or in combination with immune checkpoint inhibitors in advanced breast cancer: GlobeNewswire Inc

Jan 12, 2021

06:30AM EST -- Clinical and pathological data from clinical trial of the Bria-IMT regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021 GlobeNewswire Inc

Dec 9, 2020

09:00AM EST Disease control and survival data is presented from the clinical trials of Bria-IMT alone or in combination with immune checkpoint inhibitors in advanced breast cancer: GlobeNewswire Inc

Dec 1, 2020

06:30AM EST BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. GlobeNewswire Inc

Nov 17, 2020

04:16PM EST BriaCell Therapeutics Corp. Closes Debt Financing GlobeNewswire Inc

Nov 10, 2020

06:30AM EST -- BriaCell and National Cancer Institute to collaborate onBria-OTS,BriaCells off-the-shelf personalized immunotherapy, as a treatment for cancer. GlobeNewswire Inc

Oct 21, 2020

06:30AM EDT -- Overall Survival of 13.3 months inpatients,including 14 months in patients with Grade I/II tumors, suggesting clinical benefit; -- Comparison: 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting without BriaCells treatment; -- Additional overall survival data will be presented at the 2020 San Antonio Breast Cancer Symposium, December 9 11. GlobeNewswire Inc

Oct 6, 2020

06:30AM EDT BriaCell to Present Clinical Findings at the 2020 San Antonio GlobeNewswire Inc

Oct 1, 2020

06:30AM EDT Note from BriaCell Management October is Breast GlobeNewswire Inc

Sep 15, 2020

06:30AM EDT BriaCell to Present at the 3rd Annual Biologics World Nordic 2020 GlobeNewswire Inc

Sep 4, 2020

05:00PM EDT BriaCell Awarded Research Grant from Wiseman Cancer Research GlobeNewswire Inc

Aug 17, 2020

08:43PM EDT BriaCell Therapeutics Corp. Announces Completion of Shares for GlobeNewswire Inc

06:30AM EDT Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. GlobeNewswire Inc

Aug 11, 2020

02:51PM EDT Briacell Therapeutics Corp. Announces Shares for Debt Issuance GlobeNewswire Inc

Share